Oncology Research International Ltd
Investigate, develop new, effective & low cost plant-derived immune-oncology therapies for treatment of cancer
About Oncology Research International Ltd
ORIL is a public-unlisted biotech start-up headquartered in Adelaide, Australia;
Founded by a cancer survivor, it has been carrying on the research work in low-cost & effective treatment of cancer based on chemical compounds found in natural recurring substance, using traditional Chinese medicine (TCM) approach;
Currently the Company’s new chemical entity ORIL19 has been approved strong efficacy in curing liver & breasts cancer during pre-clinical research; the Company has been strongly encouraged & approved by US FDA to conduct clinical phase 1 research, but is in need of approx. AU$2-5m (US$1.5m) for funding the regulatory filing costs & ongoing research expenses
Founded by a cancer survivor, it has been carrying on the research work in low-cost & effective treatment of cancer based on chemical compounds found in natural recurring substance, using traditional Chinese medicine (TCM) approach;
Currently the Company’s new chemical entity ORIL19 has been approved strong efficacy in curing liver & breasts cancer during pre-clinical research; the Company has been strongly encouraged & approved by US FDA to conduct clinical phase 1 research, but is in need of approx. AU$2-5m (US$1.5m) for funding the regulatory filing costs & ongoing research expenses
Founders & Key People
Financials Beta
Business Model: Not Specified
Revenues: Not Specified
Expenses: Not Specified
Debt: Request
Operating Status: Active
Funding Raised: $0
Investment Rounds: 0 Rounds
Funding Stage: Not Specified
Last Funding Date: Not Specified
